Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Wedemeyer, H (author)

Aleman, S (author)

Brunetto, M (author)

show more...

Blank, A (author)

Andreone, P (author)

Bogomolov, P (author)

Chulanov, V (author)

Mamonova, N (author)

Geyvandova, N (author)

Viacheslav, M (author)

Sagalova, O (author)

Stepanova, T (author)

Manuilov, D (author)

Suri, V (author)

An, Q (author)

Flaherty, JF (author)

Osinusi, A (author)

Zur Wiesch, JS (author)

Cornberg, M (author)

Zeuzem, S (author)

Lampertico, P (author)

show less...

2022

2022

English.

In: JOURNAL OF HEPATOLOGY. - 0168-8278. ; 77, s. S4-S5

Related links:

http://kipublication...

• Conference paper (other academic/artistic)